Chae YK

ORCID: 0000-0003-1557-7235 · 2 papers in corpus
nonrandomized-trial 2026
Journal for immunotherapy of cancer ·doi:10.1136/jitc-2025-012805

BACKGROUND: Dual anti-CTLA-4/PD-1 inhibitors show efficacy in numerous malignancies. We are the first to report on the efficacy of ipilimumab-nivolumab immunotherapy in a dedicated cohort of patients with gynecologic clear cell carcinomas (…

case-report 2019
BMC cancer ·doi:10.1186/s12885-019-5934-4

BACKGROUND: Primary retroperitoneal serous adenocarcinoma (PRSA) is an extremely uncommon malignancy exclusively reported in females. Due to the rarity of the disease, it is difficult to establish a standardized treatment. CASE PRESENTATIO…